Please login to the form below
Pruritus
This page shows the latest Pruritus news and features for those working in and with pharma, biotech and healthcare.
Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
with urticaria, chronic pruritus and chronic obstructive pulmonary disease.
Latest news
-
Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
urticaria, chronic pruritus and chronic obstructive pulmonary disease.
-
Ipsen to acquire rare disease specialist Albireo in deal worth over $950m
patients with pruritus in progressive familial intrahepatic cholestasis (PFIC). ... paediatric liver disease for which the most debilitating symptom is severe pruritus.
-
European Commission approves potential new treatment for Pompe disease
The most frequently reported adverse drug reactions (ADRs) (> 5%) were pruritus (9.4%), rash (8%), headache (7.2%), urticaria (6.5%), fatigue (6.5%), nausea (5.8%) and chills (5.1%).
-
Menlo slumps as itching drug fails mid-stage trial
Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... It also said the data has no read-through to its lead indication for serlopitant in pruritus
-
FDA delays decision on Intercept's NASH drug by three months
The safety and tolerability profile of obeticholic acid, which is associated with pruritus, may limit the number of patients and physicians who want to use the drug, even if it is
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Body image and mental health: The psoriasis connection
4. Reich A, et al. Pruritus is an important factor negatively influencing the well-being of psoriatic patients.Acta dermato-venereologica, 2010; 90(3): 257-263.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
